Who's Who

5 Houston innovators headed to SXSW to know this week

Take a good look at these Houston entrepreneurs' faces, because you might be seeing them in downtown Austin next weekend for SXSW. Photos courtesy

Welcome to a special edition of InnovationMap's weekly innovators to know series. This week has more innovators featured than ever, and we're highlighting a particular group of people: The Houston founders headed for SXSW in Austin later this week. From startup founders, coworking space leaders, and pitch competition organizers, here's the Houston SXSW attendees you should know about.

Scott Parazynski, CEO of Fluidity Technologies

Courtesy of Fluidity

Houston-based Fluidity Technologies and its drone controller, FT Aviator, will be presenting at the 11th annual SXSW Pitch event on Saturday, March 9, at 5 p.m. The company has been named a finalist in the Hyper-Connected Communities category. Fluidity is lead by CEO Scott Parazynski, a former NASA astronaut, pilot, and physician. The FT Aviator has the potential to revolutionize drone technology. The joystick-like controller is based off movement in space, Parazynski says, and is less prone to user error by someone not as well trained in drone operation.

Fluidity will find out if it wins in its category on Sunday, March 10, at 6:30 p.m. at the SXSW Pitch awards program.

Lawson Gow, founder and CEO of The Cannon

Courtesy of The Cannon

There's no better setting to talk Texas entrepreneurialism than a stage at SXSW, and that's what Lawson Gow, founder and CEO of The Cannon, is going to be doing on the "Austinpreneur: The Texas Startup Manifesto" panel presented by Capital Factory on Saturday, March 9, at 11 am.

Gow, who is the son of InnovationMap's parent company's CEO, has been juggling a lot since the launch of Cannon Ventures last year and the anticipation of The Cannon's new West Houston 120,000-square-foot facility, which is expected to deliver in May.

Gabriella Rowe, CEO of Station Houston

Courtesy of Station Houston

Gabriella Rowe, the fearless leader of startup acceleration hub, Station Houston, is headed for the state capital to talk, well, capital. Rowe will be a panelist on the "Startup Funding: From Apprenticeships to Professions" panel on Saturday, March 9, at 12:30 pm.

Rowe has served as CEO of Station Houston since August. The nonprofit has a lot going on ahead of The Ion's launch, of which the Station is the programming partner. Read more about that — and why Rowe says wild horses couldn't drag her out of Houston —in her Featured Innovator piece.

Katharine Forth, founder and CEO of Zibrio

Courtesy of Zibrio

Another Houston company selected as a finalist of the 11th annual SXSW Pitch event is Zibrio SmartScale, which is in the Health and Wearable category and is presenting on Sunday, March 10, at 5 pm. The company is all about balance. Its product, a smart scale that tracks balance, aims to reduce dangers that come with poor balance — injuries, deaths, and costs from falls. Katharine Forth leads the company as CEO and founder. The company was a member of TMCx's 2015 medical devices cohort.

Right after pitching, Forth will find out if her company wins in its category on Sunday, March 10, at 6:30 p.m. at the SXSW Pitch awards program.

Greg Wright, founder of HATCH Pitch

Courtesy of HATCH

For the eighth year, Houston-based HATCH Pitch is headed to Austin for SXSW to host its pitch competition focused on startups making the world a better place. Greg Wright, founder of the pitch program, will be there leading the event, which takes place on Monday, March 11, from 10 am to noon. The competition will be between four finalists. While only invited guests guests can attend, the pitches will be streamed online in an interactive way, so viewers can post comments or questions to the mentors, pitchers, and judges.

Trending News

Building Houston

 
 

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

A clinical-stage company headquartered in Houston has opened an online funding campaign.

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."


Trending News